PD-1 Drug With Progesterone for Early Endometrial Cancer Seeking Fertility Preservation
Tests a PD-1 drug with progesterone in young women with early mismatch repair-deficient endometrial cancer.
Plain-language title generated from the registry record
Registry title: PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18-45 with early-stage endometrial cancer that is mismatch repair-deficient (MMRd) and who strongly want to keep their fertility.
- Age
- 18 to 45 years
- Sex
- Women only
- Disease stage
- Stage IA (FIGO 2009) endometrial adenocarcinoma, grade G1-G2, confirmed by D&C or hysteroscopy.
- Biomarker or test result
- MMRd (mismatch repair-deficient), shown by immunohistochemistry for MMR proteins and by next-generation sequencing (NGS) or microsatellite PCR.
Main reasons for not taking part
- Stage IB (FIGO 2009) or higher
- Tumour grade G3 or non-endometrioid adenocarcinoma
- Any other cancer
- Cannot have conservative treatment or the study drugs
- Cannot safely have a pregnancy or delivery, or judged unfit for it by the researcher
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT06549855, who can take part
Where in China
- Peking University People's HospitalBeijing, ChinaContact: Jianliu WangTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT06549855
- Record updated
- 10 August 2026
- Original description
The objective of this study was to investigate the feasibility of a PD-1 inhibitor in combination with progesterone as a means of preserving fertility in patients with early-stage mismatch repair-deficient (MMRd) endometrial cancer who wish to preserve fertility.Read full original descriptionShow less
PD-1 Inhibitor Combined With Progesterone Treatment in Fertility Sparing Therapy for Mismatch Repair-deficient Endometrial Cancer
The objective of this study was to investigate the feasibility of a PD-1 inhibitor in combination with progesterone as a means of preserving fertility in patients with early-stage mismatch repair-deficient (MMRd) endometrial cancer who wish to preserve fertility.
Inclusion: Be between the ages of 18-45 years old; Stage IA (FIGO 2009) ; Confirmed diagnosis of endometrial adenocarcinoma G1-G2 based upon D\&C or hysteroscopy; Molecular classification of MMRd, determined by immunohistochemical (IHC) for MMR proteins and by the second generation sequencing (NGS) or microsatellite polymerase chain reaction (PCR); With a strong desire for fertility preservation; Sign the informed consent.
Exclusion: Complicated with any other malignancy；; Stage IB(FIGO 2009) and above；; Tumour differentiation of G3 or non-endometrioid adenocarcinoma；; Contraindicated to conservative treatment or the use of pharmaceuticals; Contraindications to pregnancy, or judged by the researcher to be unfit for pregnancy or delivery.